Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (4165)	10/8/2002 3:46:59 PM
From: StockDung	Read Replies (1) \| Respond to of 5582

The ceo when asked how much cash said after we retire the debt we will have $5M sometime next year. Guess what? they have $5 M in debt. Sounds like a pump n dump to raise $10m to me, LOL Matrixx's Johnson: Financial Outlook and Zicam Products Page 1/2 New York, Oct. 8, 2002 (Bloomberg) -- Carl Johnson, chief executive of Matrixx Initiatives Inc., talks with Bloomberg's Ambre Brown Morley about the company's financial outlook, marketing strategy and its Zicam line of cold and allergy products. Matrixx changed its name from Gum Tech International Inc. in June. 01:35 Matrixx's Zicam products; outlook for competition 01:00 Change in business focus and company name since June 01:07 Financial performance; profitability outlook; new products 01:59 Acquisition strategy; product development; advertising 01:22 Marketing strategy for Zicam line; cash position 01:00 Sales outlook; 2001 loss; full-year earnings outlook For company information see MTXX <Equity> CN, BQ. For related news see the following NI codes: HEA, DRG, MEDICAL, NP, COS, CORPFIN, CEO, ERN, EST, ADV, US, NY, AZ. For more on the Bloomberg Forum see FORUM. For more Bloomberg Multimedia reports see AV. -- Bloomberg Multimedia (609) 750-4455 (AK/EC) Running time 8:03. -0- (BN ) Oct/08/2002 18:59 GMT